Drugs to Watch

These drugs are ones to keep an eye on when they get to trials.

Investigational Drugs Against the Insulin-like Growth Factor Family

For summaries about the insulin-like growth factor (IGF) signaling family, please link to these pages on our site:

• IGF Signals in GIST
• Insulin-like Growth Factor 1 Receptor in GIST

Several drugs aimed at inhibiting IGF family targets are in clinical trials at present, with some trials for which GIST patients are eligible.  Please see our page Insulin-like Growth Factor Pathway Inhibitors for those options.

Below are drugs to consider when they do appear in trials that accept GIST patients.

AMG 479

manufacturer website link Amgen, Incorporated 

oral or intravenous: Intravenous

Description from AMGEN site: AMG 479 is a fully human monoclonal antibody that binds to insulin-like growth factor-1 receptor without cross-reacting with the closely related insulin receptor.

Ongoing Trials:
This drug is in several trials, but none so far are applicable to GIST patients.
For a search on clinicaltrials.gov click here:
http://clinicaltrials.gov/ct2/results?term=AMG479

NVP-AEW541  

manufacturer website link:  Novartis 

oral or intravenous: Oral

Ongoing trials:  none yet, but one may be planned at Fox Chase based on the tesults on GIST cells at Andrew Godwin's lab (see link at top of section).

Abstracts in PubMed: click here for search results

OSI-906 

manufacturer website link  http://www.osip.com/OSI_906

oral or intravenous: Oral

Description from NCI Drug Dictionary: An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.

Trials (Phase 1) 

Phase 1 Study of Continuous OSI-906 Dosing  (NCT00514007)

Phase 1 Study of Intermittent OSI-906 Dosing  (NCT00514306)